维利帕尼和多柔比星联合作用对人肝癌耐药细胞株BEL-7404增殖和凋亡的影响

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (239 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的检测PARP抑制剂维利帕尼与抗癌药物多柔比星联合应用对肝癌耐药细胞株BEL-7404增殖抑制的作用。方法以BEL-7404为研究对象,常规培养传代,经多柔比星和（或）维利帕尼处理24 h后,通过四甲基偶氮唑盐(MTT) 比色法观察细胞的增殖率变化, 采用流式细胞术Annexin V-FITC/PI双染法分析细胞凋亡水平,通过单细胞凝胶电泳实验评价DNA损伤程度,通过聚丙烯酰胺凝胶电泳（Western blotting）法检测细胞线粒体和胞浆中细胞色素c水平变化。结果多柔比星和维利帕尼联合应用组的细胞增殖率明显低于对照组和多柔比星单独处理组（P<0.01）,细胞凋亡率则显著高于对照组和多柔比星单独处理组（P<0.05）;同时,多柔比星和维利帕尼联合应用组细胞DNA损伤水平较对照组和多柔比星单独处理组亦明显加重（P<0.01）,而细胞色素C在胞浆中的水平则显著高于对照组和多柔比星单独处理组（P<0.01）。结论维利帕尼与多柔比星联合作用可以抑制BEL-7404细胞的增殖,并诱导细胞DNA损伤和凋亡,其机制与胞浆中细胞色素c的表达升高有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李红娟
	姜英
	苏君梅
	葛卫红

关键词 ：肝癌细胞, 多柔比星, 维利帕尼, 细胞色素c, 增殖率

Abstract：ObjectiveThe aim of this study was to investigate the combined effects of veliparib and doxorubicin on the proliferation and apoptosis of human hepatocellular carcinoma cell line BEL-7404. MethodsBEL-7404 cells were taken as the object of study and conventional culture was performed. The cells were treated with doxorubicin and/or veliparib for 24h. Cell proliferation were detected by MTT assay. DNA damage and cell apoptosis were measured by comet assay and flow cytometry using annexin V-FITC/PI staining respectively. The expression of cytochrome c in the mitochondrion and cytoplasm was detected by Western blotting. ResultsCompared with the control group and doxorubicin-treated group, the cell proliferation rate in the combined-treatment group was significantly lower（P<0.01）, while the cell apoptosis rate was significantly higher（P<0.05）. Furthermore, the DNA damage in the combined-treatment group was more serious and the expression of cytochrome c in cytoplasm was up-regulated（P<0.01）.ConclusionsCombined treatment of veliparib and doxorubicin can inhibit proliferation and induce DNA damage and apoptosis in BEL-7404 cells. The mechanism probably involves increased intracellular cytochrome c expression.

Key words： Hepatocellular carcinoma cell line BEL-7404 Doxorubicin Veliparib Cytochrome c Cell proliferation Cell apoptosis

引用本文:

李红娟,姜英,苏君梅,葛卫红. 维利帕尼和多柔比星联合作用对人肝癌耐药细胞株BEL-7404增殖和凋亡的影响[J]. 实用预防医学, 2015, 22(4): 398-402. LI Hong-juan, JIANG Ying, SU Jun-mei, GE Wei-hong. Combined effects of veliparib and doxorubicin on the proliferation and apoptosis of human hepatocellular carcinoma cell line BEL-7404. , 2015, 22(4): 398-402.

链接本文:

https://www.syyfyx.com/CN/ 或 https://www.syyfyx.com/CN/Y2015/V22/I4/398

[1] Stojak M, Lukawska M, Oszczapowicz I, et al. Cell-cycle disturbance and induction of programmed death by new formamidine analogs of daunorubicin[J]. Anticancer Res, 2014, 34(12): 7151-7158.
[2] Sunter NJ, Cowell IG, Willmore E, et al. Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide[J]. J Nucleic Acids, 2010, 2010.pii: 710589.
[3] 于静,杨继章,苏素文,等. 多柔比星心脏毒性及其中药防治研究进展[J]. 医药导报, 2013,32(02): 174-177.
[4] Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond[J]. Nat Rev Cancer, 2010, 10(4): 293-301.
[5] Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles[J]. Cancer Cell, 2011, 19(2): 165-167.
[6] Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment[J]. Br Med Bull, 2009, 89: 23-40.
[7] Porcelli L, Quatrale AE, Mantuano P, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity[J]. Mol Oncol, 2013, 7(3): 308-322.
[8] To C, Kim EH, Royce DB, et al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice[J]. Cancer Prev Res (Phila), 2014, 7(7): 698-707.
[9] Corcuera LA, Arbillaga L, Vettorazzi A, et al. Ochratoxin A reduces aflatoxin B1 induced DNA damage detected by the comet assay in Hep G2 cells[J]. Food Chem Toxicol, 2011, 49(11): 2883-2889.
[10] 何裕军,刘瑞环,宁澄清,等. 多腺苷二磷酸核糖聚合酶抑制剂抗肿瘤的研究进展[J]. 药学学报, 2013,48(05): 655-660.
[11] Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling[J]. Trends Pharmacol Sci, 2004, 25(5): 259-264.
[12] Pachkowski BF, Tano K, Afonin V, et al. Cells deficient in PARP-1 show an accelerated accumulation of DNA single strand breaks, but not AP sites, over the PARP-1-proficient cells exposed to MMS[J]. Mutat Res, 2009, 671(1-2): 93-99.
[13] Farmer H, Mccabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005, 434(7035): 917-921.
[14] Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J]. Nature, 2005, 434(7035): 913-917.
[15] Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest[J]. DNA Repair (Amst), 2011, 10(10): 1003-1013.
[16] 张敬敬. PARP-1抑制剂对卵巢癌耐药细胞C13*生长活性及耐药性的影响[D]. 山东大学, 2012.
[17] Balmana J, Domchek SM, Tutt A, et al. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers[J]. Cancer Discov, 2011, 1(1): 29-34.
[18] Zimmermann KC, Waterhouse NJ, Goldstein JC, et al. Aspirin induces apoptosis through release of cytochrome c from mitochondria[J]. Neoplasia, 2000, 2(6): 505-513.